Randomized, Placebo-Controlled, Crossover Trial of Memantine for Cognitive Changes with Corticosteroid Therapy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: In animal models, corticosteroids are associated with changes in hippocampal structure and functioning that are prevented by glutamate release inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists. Cushing's disease and prescription corticosteroid administration are also associated with memory impairment and hippocampal atrophy. Use of NMDA receptor antagonists to attenuate corticosteroid effects in humans has not been investigated. We examine the NMDA receptor antagonist memantine in patients receiving corticosteroids. Methods: Twenty outpatients receiving long-term oral corticosteroid therapy were randomized to 8 weeks of memantine (maximum dose 20 mg/day) and 8 weeks of placebo in a double-blind fashion, with a 4-week washout period between courses. Declarative memory was assessed with the Hopkins Verbal Learning Test (HVLT) and mood with the Hamilton Rating Scale for Depression and Young Mania Rating Scale. Changes in outcome measures were compared during memantine and placebo exposure. Results: Seventeen participants completed both treatment phases and were used in the analysis. Significant improvement (p < .05) in total and delayed recall on the HVLT was observed with memantine as compared with placebo. No significant changes in mood were observed. Conclusions: Memantine therapy was associated with improvement in declarative memory but not mood in patients receiving prescription corticosteroids.

Original languageEnglish (US)
Pages (from-to)727-729
Number of pages3
JournalBiological Psychiatry
Volume64
Issue number8
DOIs
StatePublished - Oct 15 2008

Fingerprint

Memantine
Cross-Over Studies
Adrenal Cortex Hormones
Placebos
N-Methyl-D-Aspartate Receptors
Verbal Learning
Prescriptions
Therapeutics
Pituitary ACTH Hypersecretion
Bipolar Disorder
Atrophy
Glutamic Acid
Outpatients
Animal Models
Outcome Assessment (Health Care)
Depression

Keywords

  • Corticosteroid
  • depression
  • hippocampus
  • mania
  • memantine
  • memory

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

@article{d1f153e681834483871d61184df30d17,
title = "Randomized, Placebo-Controlled, Crossover Trial of Memantine for Cognitive Changes with Corticosteroid Therapy",
abstract = "Background: In animal models, corticosteroids are associated with changes in hippocampal structure and functioning that are prevented by glutamate release inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists. Cushing's disease and prescription corticosteroid administration are also associated with memory impairment and hippocampal atrophy. Use of NMDA receptor antagonists to attenuate corticosteroid effects in humans has not been investigated. We examine the NMDA receptor antagonist memantine in patients receiving corticosteroids. Methods: Twenty outpatients receiving long-term oral corticosteroid therapy were randomized to 8 weeks of memantine (maximum dose 20 mg/day) and 8 weeks of placebo in a double-blind fashion, with a 4-week washout period between courses. Declarative memory was assessed with the Hopkins Verbal Learning Test (HVLT) and mood with the Hamilton Rating Scale for Depression and Young Mania Rating Scale. Changes in outcome measures were compared during memantine and placebo exposure. Results: Seventeen participants completed both treatment phases and were used in the analysis. Significant improvement (p < .05) in total and delayed recall on the HVLT was observed with memantine as compared with placebo. No significant changes in mood were observed. Conclusions: Memantine therapy was associated with improvement in declarative memory but not mood in patients receiving prescription corticosteroids.",
keywords = "Corticosteroid, depression, hippocampus, mania, memantine, memory",
author = "Brown, {E. Sherwood} and Miguel Vazquez and Alyson Nakamura",
year = "2008",
month = "10",
day = "15",
doi = "10.1016/j.biopsych.2008.05.010",
language = "English (US)",
volume = "64",
pages = "727--729",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Randomized, Placebo-Controlled, Crossover Trial of Memantine for Cognitive Changes with Corticosteroid Therapy

AU - Brown, E. Sherwood

AU - Vazquez, Miguel

AU - Nakamura, Alyson

PY - 2008/10/15

Y1 - 2008/10/15

N2 - Background: In animal models, corticosteroids are associated with changes in hippocampal structure and functioning that are prevented by glutamate release inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists. Cushing's disease and prescription corticosteroid administration are also associated with memory impairment and hippocampal atrophy. Use of NMDA receptor antagonists to attenuate corticosteroid effects in humans has not been investigated. We examine the NMDA receptor antagonist memantine in patients receiving corticosteroids. Methods: Twenty outpatients receiving long-term oral corticosteroid therapy were randomized to 8 weeks of memantine (maximum dose 20 mg/day) and 8 weeks of placebo in a double-blind fashion, with a 4-week washout period between courses. Declarative memory was assessed with the Hopkins Verbal Learning Test (HVLT) and mood with the Hamilton Rating Scale for Depression and Young Mania Rating Scale. Changes in outcome measures were compared during memantine and placebo exposure. Results: Seventeen participants completed both treatment phases and were used in the analysis. Significant improvement (p < .05) in total and delayed recall on the HVLT was observed with memantine as compared with placebo. No significant changes in mood were observed. Conclusions: Memantine therapy was associated with improvement in declarative memory but not mood in patients receiving prescription corticosteroids.

AB - Background: In animal models, corticosteroids are associated with changes in hippocampal structure and functioning that are prevented by glutamate release inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists. Cushing's disease and prescription corticosteroid administration are also associated with memory impairment and hippocampal atrophy. Use of NMDA receptor antagonists to attenuate corticosteroid effects in humans has not been investigated. We examine the NMDA receptor antagonist memantine in patients receiving corticosteroids. Methods: Twenty outpatients receiving long-term oral corticosteroid therapy were randomized to 8 weeks of memantine (maximum dose 20 mg/day) and 8 weeks of placebo in a double-blind fashion, with a 4-week washout period between courses. Declarative memory was assessed with the Hopkins Verbal Learning Test (HVLT) and mood with the Hamilton Rating Scale for Depression and Young Mania Rating Scale. Changes in outcome measures were compared during memantine and placebo exposure. Results: Seventeen participants completed both treatment phases and were used in the analysis. Significant improvement (p < .05) in total and delayed recall on the HVLT was observed with memantine as compared with placebo. No significant changes in mood were observed. Conclusions: Memantine therapy was associated with improvement in declarative memory but not mood in patients receiving prescription corticosteroids.

KW - Corticosteroid

KW - depression

KW - hippocampus

KW - mania

KW - memantine

KW - memory

UR - http://www.scopus.com/inward/record.url?scp=52949153576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949153576&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2008.05.010

DO - 10.1016/j.biopsych.2008.05.010

M3 - Article

C2 - 18582848

AN - SCOPUS:52949153576

VL - 64

SP - 727

EP - 729

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 8

ER -